Depo-Provera Litigation Update: FDA Warning and MDL Growth (January 2026)

The Depo-Provera MDL surpassed 2,100 cases as of January 2026. On December 12, 2025, the FDA added a meningioma warning to the contraceptive injection's label, altering Pfizer's preemption defense as the litigation heads toward bellwether proceedings. A 2024 BMJ study previously established that women using the injectable contraceptive for over one year face a 5.5-fold increased risk of developing intracranial meningiomas.

The litigation centers on allegations that Pfizer failed to warn patients and prescribing physicians about brain tumor risks associated with medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera. With millions of women having used the contraceptive since its 1992 FDA approval, the claimant pool remains substantial.

Case Background and Timeline

The Depo-Provera litigation accelerated in 2025 following peer-reviewed studies linking the contraceptive to intracranial tumors:

Medical and Scientific Evidence

Two primary studies form the scientific foundation for general causation in MDL 3140:

BMJ Study (March 2024)

The British Medical Journal published a French national case-control study analyzing health data from 2009 to 2018. Researchers found that women using injectable progestogens like Depo-Provera had 5.55× higher odds of developing intracranial meningiomas. Risk increased with duration of use, particularly beyond one year of continuous use.

JAMA Neurology Study (November 2025)

A Cleveland Clinic and Case Western Reserve University study analyzed U.S. patient records, confirming a 2.43× increased risk among Depo-Provera users. The study noted elevated risk among:

• Women who began use after age 31
• Women who used the drug continuously for more than four years

Impact on Pending Litigation

The FDA label change weakens Pfizer's primary preemption defense, which argued that federal regulations prevented adding a meningioma warning without prior FDA direction.

Key Pretrial Proceedings

Preemption briefing: Following the FDA update, Judge Rodgers ordered supplemental briefing to evaluate how the revised label affects Pfizer's summary judgment motion.

Bellwether selection: The court selected five bellwether cases for initial trial preparation to evaluate causation and damages.

Case Qualification and Medical Records

Qualification Criteria

Evaluating claimant eligibility requires establishing:

• Product identification: Documented use of brand Depo-Provera, Depo-SubQ Provera 104, or generic medroxyprogesterone acetate injections
• Duration of exposure: At least one year of continuous use (longer use supports causation)
• Clinical diagnosis: Confirmed intracranial meningioma via MRI or CT imaging
• Exposure timing: Use of the drug prior to the December 2025 FDA label revision

Essential Medical Documentation

1. Prescription and administration logs: Documenting specific injection dates, dosages, and provider names
2. Diagnostic imaging: Brain MRI and CT scans confirming meningioma pathology
3. Surgical and pathology reports: Biopsy confirmation following craniotomy or tumor resection
4. Neurology treatment charts: Clinical notes, medication management, and symptom monitoring
5. Pharmacy fill records: Corroborating continuous prescription dispensations

LlamaLab retrieves records from OB/GYN offices, pharmacies, and neurosurgery departments in 4 days on average (with ~30-40% returned same-day on electronic requests) and uses insurance data to surface treatment locations clients don't always remember. Invoices are itemized per case to flow through as recoverable case disbursements on settlement statements.

Next Steps in MDL 3140

Statute of Limitations Considerations

Statutes of limitations vary by state, generally running 2 to 3 years from injury discovery:

• Discovery rule: The limitation period generally starts when the claimant knew or should have known of the connection between Depo-Provera and their tumor
• Regulatory trigger: The December 2025 FDA label update may establish new notice dates under state discovery rules
• Scientific publications: Landmark studies in BMJ (March 2024) and JAMA Neurology (November 2025) serve as evidentiary reference points

Summary

With over 2,100 filed cases, an updated FDA warning label, and bellwether trials set for late 2026, the Depo-Provera litigation is moving through pretrial milestones. Documenting exposure history and tumor pathology early ensures claimant files are prepared for trial pool selection and settlement tiering.

Sources: MDL Update, FLND Court MDL 3140, Drugwatch, The Legal Link, TSEG, The Guardian. Case counts current as of January 2026.

This article provides general information about Depo-Provera litigation developments and does not constitute legal or medical advice.